In particular, human medulloblastomas of the SHH subgroup, accounting for ~30% of all medulloblastomas, arise mostly due to mutations in the PTCH1 receptor, the transmembrane activator Smoothened, the signal transduction modulator SUFU and transcriptional regulator GLI2 [6,7,12]. The gene discussed is GLI2; the disease is medulloblastoma.